Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diabetic retinopathy
Biotech
Valo abandons ROCK inhibitor after diabetic retinopathy fail
Valo's ROCK 1 and 2 inhibitor failed to reduce the severity of diabetic retinopathy, leading the Flagship-founded biotech to drop the candidate.
James Waldron
Jan 2, 2025 9:43am
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
Mar 14, 2024 9:15am
Roche drops oral eye disease drug after completing phase 2
Oct 19, 2023 5:50am
Ocuphire's diabetic eye drug misses phase 2 primary endpoint
Jan 26, 2023 8:32am
Eye AI? Aye-aye, FDA tells AEYE
Nov 17, 2022 10:26am
Eyenuk scopes out $26M for diabetes eye screening AI
Oct 17, 2022 12:01pm
